Pierre Blier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11044346/publications.pdf

Version: 2024-02-01

16791 17373 126 17,902 216 66 citations h-index g-index papers 218 218 218 12567 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 115, 110507.	2.5	10
2	The Effects of Ketamine on Cognition in Unipolar and Bipolar Depression. Journal of Clinical Psychiatry, 2022, 83, .	1.1	7
3	Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder. International Journal of Neuropsychopharmacology, 2022, 25, 283-292.	1.0	5
4	The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Conc L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.	er na9 it	54
5	Canadian Journal of Psychiatry, 2021, 66, 113-125. Repeated but Not Single Administration of Ketamine Prolongs Increases of the Firing Activity of Norepinephrine and Dopamine Neurons. International Journal of Neuropsychopharmacology, 2021, 24, 570-579.	1.0	16
6	The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder. International Journal of Neuropsychopharmacology, 2020, 23, 230-256.	1.0	38
7	Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology, 2020, 45, 606-612.	2.8	68
8	Long-term administration of cariprazine increases locus coeruleus noradrenergic neurons activity and serotonin _{1A} receptor neurotransmission in the hippocampus. Journal of Psychopharmacology, 2020, 34, 1143-1154.	2.0	5
9	Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. Focus (American Psychiatric Publishing), 2020, 18, 236-243.	0.4	3
10	A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol. BMC Psychiatry, 2020, 20, 268.	1.1	16
11	Triple reuptake inhibition of serotonin, norepinephrine, and dopamine increases the tonic activation of $\hat{l}\pm 2$ -adrenoceptors in the rat hippocampus and dopamine levels in the nucleus accumbens. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 103, 109987.	2.5	5
12	Serotonin-2B receptor antagonism increases the activity of dopamine and glutamate neurons in the presence of selective serotonin reuptake inhibition. Neuropsychopharmacology, 2020, 45, 2098-2105.	2.8	9
13	Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). International Journal of Neuropsychopharmacology, 2019, 22, 616-630.	1.0	404
14	Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression. JAMA Psychiatry, 2019, 76, 893.	6.0	472
15	Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. American Journal of Psychiatry, 2019, 176, 401-409.	4.0	266
16	Switching medication products during the treatment of psychiatric illness. International Journal of Psychiatry in Clinical Practice, 2019, 23, 2-13.	1.2	11
17	Synergistic effect of aripiprazole and escitalopram in increasing serotonin but not norepinephrine neurotransmission in the rat hippocampus. Neuropharmacology, 2019, 146, 12-18.	2.0	9
18	Ketamine for chronic depression: two cautionary tales. Journal of Psychiatry and Neuroscience, 2019, 44, 384-385.	1.4	9

#	Article	IF	CITATIONS
19	Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient. International Journal of Neuropsychopharmacology, 2018, 21, 128-144.	1.0	68
20	Pre-treatment EEG signal variability is associated with treatment success in depression. NeuroImage: Clinical, 2018, 17, 368-377.	1.4	36
21	The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study. Journal of Affective Disorders, 2018, 227, 542-549.	2.0	59
22	Partial inhibition of catecholamine activity and enhanced responsiveness to NMDA after sustained administration of vortioxetine. Neuropharmacology, 2018, 128, 425-432.	2.0	7
23	Optimized regimens of combined medications for the treatment of major depressive disorder: a double-blind, randomized-controlled trial. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 3209-3218.	1.0	4
24	Involvement of 5-HT _{1A} and 5-HT _{2A} Receptors but Not <i<math>\hat{l}+<csub>2-Adrenoceptors in the Acute Electrophysiological Effects of Cariprazine in the Rat Brain In Vivo. Molecular Pharmacology, 2018, 94, 1363-1370.</csub></i<math>	1.0	12
25	The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults (CINP-BD-2017), part 3: The clinical guidelines International Journal of Neuropsychopharmacology, 2017, 20, pyw109.	1.0	151
26	The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 4: Unmet Needs in the Treatment of Bipolar Disorder and Recommendations for Future Research. International Journal of Neuropsychopharmacology, 2017, 20, pyw072.	1.0	44
27	Progress on the Neuroscience-Based Nomenclature (NbN) for Psychotropic Medications. Neuropsychopharmacology, 2017, 42, 1927-1928.	2.8	6
28	Effects of levomilnacipran ER on noradrenergic symptoms, anxiety symptoms, and functional impairment in adults with major depressive disorder: Post hoc analysis of 5 clinical trials. Journal of Affective Disorders, 2017, 210, 273-279.	2.0	5
29	The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatric Disease and Treatment, 2016, 12, 541.	1.0	56
30	Altered monoamine system activities after prenatal and adult stress: A role for stress resilience?. Brain Research, 2016, 1642, 409-418.	1.1	15
31	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 540-560.	0.9	746
32	A Neuroscience-Based Nomenclature (NbN) for Psychotropic Agents. International Journal of Neuropsychopharmacology, 2016, 19, pyw066.	1.0	13
33	The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm. International Journal of Neuropsychopharmacology, 2016, 20, pyw100.	1.0	77
34	The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 1: Background and Methods of the Development of Guidelines. International Journal of Neuropsychopharmacology, 2016, 20, pyw091.	1.0	28
35	Neuroscience-based Nomenclature (NbN) for <i>Journal of Psychopharmacology</i> Psychopharmacology, 2016, 30, 413-415.	2.0	35
36	The separate and combined effects of monoamine oxidase A inhibition and nicotine on resting state EEG. Journal of Psychopharmacology, 2016, 30, 56-62.	2.0	4

#	Article	IF	Citations
37	Brexpiprazole Alters Monoaminergic Systems following Repeated Administration: an in Vivo Electrophysiological Study. International Journal of Neuropsychopharmacology, 2016, 19, pyv111.	1.0	9
38	Restoration of Serotonin Neuronal Firing Following Long-Term Administration of Bupropion but Not Paroxetine in Olfactory Bulbectomized Rats. International Journal of Neuropsychopharmacology, 2015, 18, pyu050-pyu050.	1.0	13
39	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology, 2015, 29, 459-525.	2.0	528
40	Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy. International Journal of Psychiatry in Clinical Practice, 2015, 19, 158-167.	1.2	24
41	Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: electrophysiological studies in the rat brain. Psychopharmacology, 2015, 232, 2343-2352.	1.5	25
42	Asenapine alters the activity of monoaminergic systems following its subacute and long-term administration: An in vivo electrophysiological characterization. European Neuropsychopharmacology, 2015, 25, 531-543.	0.3	18
43	A Prospective, Longitudinal Study of the Effect of Remission on Cortical Thickness and Hippocampal Volume in Patients with Treatment-Resistant Depression. International Journal of Neuropsychopharmacology, 2015, 18, pyv037-pyv037.	1.0	107
44	A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. European Neuropsychopharmacology, 2015, 25, 2318-2325.	0.3	135
45	Long-term administration of the antidepressant vilazodone modulates rat brain monoaminergic systems. Neuropharmacology, 2015, 99, 696-704.	2.0	13
46	The separate and combined effects of monoamine oxidase A inhibition and nicotine on the mismatch negativity event related potential. Pharmacology Biochemistry and Behavior, 2015, 137, 44-52.	1.3	7
47	Antidepressant drug development: Focus on triple monoamine reuptake inhibition. Journal of Psychopharmacology, 2015, 29, 526-544.	2.0	33
48	Acute Effects of Brexpiprazole on Serotonin, Dopamine, and Norepinephrine Systems: An In Vivo Electrophysiologic Characterization. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 585-595.	1.3	38
49	Rational site-directed pharmacotherapy for major depressive disorder. International Journal of Neuropsychopharmacology, 2014, 17, 997-1008.	1.0	19
50	Examining relations between alpha power as well as anterior cingulate cortex-localized theta activity and response to single or dual antidepressant pharmacotherapies. Journal of Psychopharmacology, 2014, 28, 587-595.	2.0	16
51	Combination antidepressant therapy for major depressive disorder: Speed and probability of remission. Journal of Psychiatric Research, 2014, 52, 7-14.	1.5	33
52	Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry, 2014, 14, S1.	1,1	569
53	Response prediction to antidepressants using scalp and source-localized loudness dependence of auditory evoked potential (LDAEP) slopes. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 44, 100-107.	2.5	48
54	Serotonin and beyond: therapeutics for major depression. Philosophical Transactions of the Royal Society B: Biological Sciences, 2013, 368, 20120536.	1.8	188

#	Article	IF	CITATIONS
55	Monoamine neurocircuitry in depression and strategies for new treatments. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 45, 54-63.	2.5	432
56	Electrophysiological Effects of Repeated Administration of Agomelatine on the Dopamine, Norepinephrine, and Serotonin Systems in the Rat Brain. Neuropsychopharmacology, 2013, 38, 275-284.	2.8	76
57	Electrophysiological and neurochemical effects of long-term vagus nerve stimulation on the rat monoaminergic systems. International Journal of Neuropsychopharmacology, 2013, 16, 459-470.	1.0	136
58	Effects of repeated electroconvulsive shocks on catecholamine systems: Electrophysiological studies in the rat brain. Synapse, 2013, 67, 716-727.	0.6	13
59	Modulation of the Antidepressant-Like Effects of Sustained Administration of Carisbamate and Lamotrigine on Monoaminergic Systems: Electrophysiological Studies in the Rat Brain. Journal of Pharmacology and Experimental Therapeutics, 2013, 347, 487-496.	1.3	13
60	Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain. Journal of Psychiatry and Neuroscience, 2012, 37, 113-121.	1.4	31
61	Effects of Sustained Administration of Quetiapine Alone and in Combination with a Serotonin Reuptake Inhibitor on Norepinephrine and Serotonin Transmission. Neuropsychopharmacology, 2012, 37, 1717-1728.	2.8	38
62	Altered response to the selective serotonin reuptake inhibitor escitalopram in mice heterozygous for the serotonin transporter: an electrophysiological and neurochemical study. International Journal of Neuropsychopharmacology, 2012, 15, 349-361.	1.0	21
63	An enhancement of the firing activity of dopamine neurons as a common denominator of antidepressant treatments?. International Journal of Neuropsychopharmacology, 2012, 15, 551-553.	1.0	3
64	Electrophysiological impact of trazodone on the dopamine and norepinephrine systems in the rat brain. European Neuropsychopharmacology, 2012, 22, 518-526.	0.3	28
65	Alpha power, alpha asymmetry and anterior cingulate cortex activity in depressed males and females. Journal of Psychiatric Research, 2012, 46, 1483-1491.	1.5	173
66	A framework to avoid irrational polypharmacy in psychiatry. Journal of Psychopharmacology, 2012, 26, 1507-1511.	2.0	10
67	On the Safety and Benefits of Repeated Intravenous Injections of Ketamine For Depression. Biological Psychiatry, 2012, 72, e11-e12.	0.7	57
68	Novel attempts to optimize vagus nerve stimulation parameters on serotonin neuronal firing activity in the rat brain. Brain Stimulation, 2012, 5, 422-429.	0.7	20
69	Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 1-48.	1.8	113
70	Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 13-22.	1.8	21
71	Strategies to achieve clinical effectiveness: Refining existing therapies and pursuing emerging targets. Journal of Affective Disorders, 2011, 132, S21-S28.	2.0	17
72	The noradrenergic symptom cluster: clinical expression and neuropharmacology. Neuropsychiatric Disease and Treatment, 2011, 7, 15.	1.0	37

#	Article	IF	Citations
73	Brain Regional α-[¹¹ C]Methyl- <scp>L</scp> -Tryptophan Trapping in Medication-Free Patients With Obsessive-Compulsive Disorder. Archives of General Psychiatry, 2011, 68, 732.	13.8	25
74	Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder. Journal of Affective Disorders, 2011, 128, S3-S10.	2.0	46
75	General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 207-245.	1.8	40
76	Enhancement of serotonergic and noradrenergic neurotransmission in the rat hippocampus by sustained administration of bupropion. Psychopharmacology, 2011, 217, 61-73.	1.5	27
77	Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons. International Journal of Neuropsychopharmacology, 2011, 14, 211-223.	1.0	23
78	Pharmacological Blockade of 5-HT7 Receptors as a Putative Fast Acting Antidepressant Strategy. Neuropsychopharmacology, 2011, 36, 1275-1288.	2.8	117
79	Reply to Smith Letter. American Journal of Psychiatry, 2010, 167, 995-996.	4.0	0
80	Sustained Administration of Trazodone Enhances Serotonergic Neurotransmission: In Vivo Electrophysiological Study in the Rat Brain. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 197-206.	1.3	24
81	Effects of acute and sustained administration of the catecholamine reuptake inhibitor nomifensine on the firing activity of 2 J monoaminergic neurons. Journal of Psychopharmacology, 2010, 24, 1223-1235.	2.0	29
82	Combination of Antidepressant Medications From Treatment Initiation for Major Depressive Disorder: A Double-Blind Randomized Study. American Journal of Psychiatry, 2010, 167, 281-288.	4.0	276
83	Altered Function of the Serotonin 1A Autoreceptor and the Antidepressant Response. Neuron, 2010, 65, 1-2.	3.8	43
84	Relevance of Norepinephrine–Dopamine Interactions in the Treatment of Major Depressive Disorder. CNS Neuroscience and Therapeutics, 2010, 16, e1-17.	1.9	119
85	Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area. International Journal of Neuropsychopharmacology, 2009, 12, 475.	1.0	22
86	Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. Psychopharmacology, 2009, 206, 335-344.	1.5	44
87	Electrophysiological characterization of the effects of asenapine at 5-HT1A, 5-HT2A, $\hat{l}\pm 2$ -adrenergic and D2 receptors in the rat brain. European Neuropsychopharmacology, 2009, 19, 177-187.	0.3	47
88	Optimization of vagus nerve stimulation parameters using the firing activity of serotonin neurons in the rat dorsal raphe. European Neuropsychopharmacology, 2009, 19, 250-255.	0.3	38
89	Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation. European Neuropsychopharmacology, 2009, 19, 457-465.	0.3	122
90	Prospect of a Dopamine Contribution in the Next Generation of Antidepressant Drugs: The Triple Reuptake Inhibitors. Current Drug Targets, 2009, 10, 1069-1084.	1.0	73

#	Article	IF	CITATIONS
91	Brain Norepinephrine System as a Target for Antidepressant and Mood Stabilizing Medications. Current Drug Targets, 2009, 10, 1061-1068.	1.0	21
92	Optimal use of antidepressants: when to act?. Journal of Psychiatry and Neuroscience, 2009, 34, 80.	1.4	7
93	Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area. Journal of Psychiatry and Neuroscience, 2009, 34, 223-9.	1.4	80
94	Enhancement of the function of rat serotonin and norepinephrine neurons by sustained vagus nerve stimulation. Journal of Psychiatry and Neuroscience, 2009, 34, 272-80.	1.4	117
95	Effects of Acute and Chronic Administration of the Serotonin1A Agonist Buspirone on Serotonin Synthesis in the Rat Brain. Journal of Neurochemistry, 2008, 72, 2022-2031.	2.1	73
96	Neurokinin-1 receptor antagonists modulate brain noradrenaline and serotonin interactions. European Journal of Pharmacology, 2008, 600, 64-70.	1.7	13
97	Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. International Journal of Neuropsychopharmacology, 2008, 11 , 625 - 639 .	1.0	242
98	Sustained administration of bupropion alters the neuronal activity of serotonin, norepinephrine but not dopamine neurons in the rat brain. Neuropharmacology, 2008, 55, 1191-1198.	2.0	52
99	Cross-Talk between Dopaminergic and Noradrenergic Systems in the Rat Ventral Tegmental Area, Locus Ceruleus, and Dorsal Hippocampus. Molecular Pharmacology, 2008, 74, 1463-1475.	1.0	129
100	Clinical Evidence and Potential Neurobiological Underpinnings of Unresolved Symptoms of Depression. Journal of Clinical Psychiatry, 2008, 69, 246-258.	1.1	128
101	Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. International Journal of Neuropsychopharmacology, 2007, 10, 41.	1.0	43
102	Which antidepressants have demonstrated superior efficacy? A review of the evidence. International Clinical Psychopharmacology, 2007, 22, 323-329.	0.9	137
103	Differential physiological effects of a low dose and high doses of venlafaxine in major depression. International Journal of Neuropsychopharmacology, 2007, 10, 51.	1.0	115
104	Effect of long-term administration of the antidepressant drug milnacipran on serotonergic and noradrenergic neurotransmission in the rat hippocampus. Life Sciences, 2007, 81, 166-176.	2.0	6
105	Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin function. European Neuropsychopharmacology, 2007, 17 , $328-338$.	0.3	47
106	The importance of serotonin and noradrenaline in anxiety. International Journal of Psychiatry in Clinical Practice, 2007, 11, 16-23.	1.2	12
107	Noradrenergic Augmentation of Escitalopram Response by Risperidone: Electrophysiologic Studies in the Rat Brain. Biological Psychiatry, 2007, 61, 671-678.	0.7	85
108	Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology, 2007, 194, 63-72.	1.5	56

#	Article	IF	Citations
109	The usefulness of large studies in psychopharmacology: understanding their strong points and their drawbacks. Journal of Psychiatry and Neuroscience, 2007, 32, 232-3.	1.4	0
110	Preventing recurrent depression: long-term treatment for major depressive disorder. Journal of Clinical Psychiatry, 2007, 68, e06.	1.1	15
111	Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 362-373.	2.5	116
112	Pharmacotherapies in the Management of Obsessiveâ€"Compulsive Disorder. Canadian Journal of Psychiatry, 2006, 51, 417-430.	0.9	42
113	Catecholaminergic Strategies for the Treatment of Major Depression. Current Drug Targets, 2006, 7, 149-158.	1.0	62
114	Physiologic mechanisms underlying the antidepressant discontinuation syndrome. Journal of Clinical Psychiatry, 2006, 67 Suppl 4, 8-13.	1.1	13
115	Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: Comparison with antidepressant drugs. Peptides, 2005, 26, 1383-1393.	1.2	65
116	Atypical antipsychotics for mood and anxiety disorders: safe and effective adjuncts?. Journal of Psychiatry and Neuroscience, 2005, 30, 232-3.	1.4	9
117	Responsiveness of 5-HT(1A) and 5-HT2 receptors in the rat orbitofrontal cortex after long-term serotonin reuptake inhibition. Journal of Psychiatry and Neuroscience, 2005, 30, 268-74.	1.4	30
118	Electrophysiological Evidence for the Tonic Activation of 5-HT1A Autoreceptors in the Rat Dorsal Raphe Nucleus. Neuropsychopharmacology, 2004, 29, 1800-1806.	2.8	70
119	Frequency-dependence of serotonin autoreceptor but not ?2-adrenoceptor inhibition of [3H]-serotonin release in rat hypothalamic slices. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 339-339, 60-64.	1.4	29
120	A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biological Psychiatry, 2004, 55, 553-555.	0.7	145
121	Effects of sustained gamma-hydroxybutyrate treatments on spontaneous and evoked firing activity of locus coeruleus norepinephrine neurons. Biological Psychiatry, 2004, 55, 934-939.	0.7	34
122	In-vivo modulation of central 5-hydroxytryptamine (5-HT1A) receptor-mediated responses by the cholinergic system. International Journal of Neuropsychopharmacology, 2004, 7, 391-399.	1.0	16
123	Measurement of Brain Regional \hat{l} ±-[11C]Methyl-L-Tryptophan Trapping as a Measure of Serotonin Synthesis in Medication-FreePatients With Major Depression. Archives of General Psychiatry, 2004, 61, 556.	13.8	116
124	Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. Journal of Psychiatry and Neuroscience, 2004, 29, 208-18.	1.4	44
125	Is there a role for 5-HT1A agonists in the treatment of depression?. Biological Psychiatry, 2003, 53, 193-203.	0.7	492
126	The pharmacology of putative early-onset antidepressant strategies. European Neuropsychopharmacology, 2003, 13, 57-66.	0.3	219

#	Article	IF	CITATIONS
127	Enhancing action of LSD on neuronal responsiveness to serotonin in a brain structure involved in obsessive–compulsive disorder. International Journal of Neuropsychopharmacology, 2003, 6, 13-21.	1.0	8
128	Neurochemical and Psychotropic Effects of Bupropion in Healthy Male Subjects. Journal of Clinical Psychopharmacology, 2003, 23, 233-239.	0.7	42
129	Title is missing!. Journal of Clinical Psychopharmacology, 2003, 23, 233-239.	0.7	15
130	Effects of Serotonin (5-Hydroxytryptamine, 5-HT) Reuptake Inhibition Plus 5-HT2A Receptor Antagonism on the Firing Activity of Norepinephrine Neurons. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 983-991.	1.3	89
131	Neurokinin-1 receptors are decreased in major depressive disorder. NeuroReport, 2002, 13, 1223-1227.	0.6	57
132	Toward Optimal Treatments for Major Depression. CNS Spectrums, 2002, 7, 148-154.	0.7	3
133	Modification of serotonin neuron properties in mice lacking 5-HT1A receptors. European Journal of Pharmacology, 2002, 435, 195-203.	1.7	62
134	Serotonin 1A Receptor Activation and Hypothermia in Humans Lack of Evidence for a Presynaptic Mediation. Neuropsychopharmacology, 2002, 27, 301-308.	2.8	54
135	Effects of serotine receptors agonists, TFMPP and CGS12066B, on regional serotonin synthesis in the rat brain: an autoradiographic study. Journal of Neurochemistry, 2002, 80, 788-798.	2.1	38
136	Selecting Methodologies for the Evaluation of Differences in Time to Response Between Antidepressants. Journal of Clinical Psychiatry, 2002, 63, 694-699.	1.1	41
137	Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission. Biological Psychiatry, 2001, 50, 191-199.	0.7	73
138	Effects of chronic antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiologic activity. Biological Psychiatry, 2001, 50, 644.	0.7	7
139	Response of the Norepinephrine System to Antidepressant Drugs. CNS Spectrums, 2001, 6, 679-688.	0.7	25
140	Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology, 2001, 155, 52-57.	1.5	148
141	Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons. European Journal of Neuroscience, 2001, 13, 2077-2087.	1.2	97
142	Serotonin1A receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABAA receptors: A microiontophoretic study in the rat locus coeruleus. Synapse, 2001, 42, 203-212.	0.6	72
143	Enhancement of serotoninergic function? a sometimes insufficient cause of antidepressant action. Human Psychopharmacology, 2001, 16, 23-27.	0.7	14
144	Reduction in serotonin synthesis following acute and chronic treatments with paroxetine, a selective serotonin reuptake inhibitor, in rat brain: an autoradiographic study with α-[14 C]methyl- l-tryptophan 2 2Abbreviations: 5-HT, serotonin, 5-hydroxytryptamine; α-[14C]MTrp, α-[14C]methyl-l-tryptophan; SSRI, selective serotonin reuptake inhibitor; and α-[14C]M5HT, α-[14C]methyl-5-HT Biochemical Pharmacology, 2001, 62, 1481-1489.	2.0	26

#	Article	IF	Citations
145	Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. Brain Research, 2001, 922, 9-20.	1.1	121
146	Effects of the Selective Norepinephrine Reuptake Inhibitor Reboxetine on Norepinephrine and Serotonin Transmission in the Rat Hippocampus. Neuropsychopharmacology, 2001, 25, 845-857.	2.8	57
147	Brain Regional \hat{l} ±-[11C]Methyl-l-Tryptophan Trapping in Impulsive Subjects With Borderline Personality Disorder. American Journal of Psychiatry, 2001, 158, 775-782.	4.0	217
148	Effect of neurokinin-1 receptor antagonists on the function of 5-HT and noradrenaline neurons. NeuroReport, 2000, 11, 1323-1327.	0.6	51
149	Role of cholinergic and GABAergic systems in the feedback inhibition of dorsal raphe 5-HT neurons. NeuroReport, 2000, 11, 3397-3401.	0.6	23
150	Effect of the \hat{l}^2 -adrenoceptor agonist flerobuterol on serotonin synthesis in the rat brain. Biochemical Pharmacology, 2000, 59, 673-679.	2.0	4
151	Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. International Journal of Neuropsychopharmacology, 2000, 3, 1-11.	1.0	125
152	Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. In vivo electrophysiological studies in the rat. Neuropharmacology, 2000, 39, 1800-1812.	2.0	54
153	Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: II. In vitro studies in the rat. Neuropharmacology, 2000, 39, 1813-1822.	2.0	18
154	Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. European Neuropsychopharmacology, 2000, 10, 177-188.	0.3	68
155	Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. British Journal of Pharmacology, 1999, 126, 568-571.	2.7	95
156	Electrophysiological examination of the effects of sustained flibanserin administration on serotonin receptors in rat brain. British Journal of Pharmacology, 1999, 126, 627-638.	2.7	17
157	Serotonin and Drug-Induced Therapeutic Responses in Major Depression, Obsessive–Compulsive and Panic Disorders. Neuropsychopharmacology, 1999, 21, 91S-98S.	2.8	236
158	Venlafaxine: Discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites. , 1999, 32, 198-211.		63
159	Assessment of the serotonin reuptake blocking property of YM992: Electrophysiological studies in the rat hippocampus and dorsal raphe., 1999, 34, 277-289.		13
160	Effect of sustained administration of the 5-HT1A receptor agonist flesinoxan on rat 5-HT neurotransmission. European Neuropsychopharmacology, 1999, 9, 427-440.	0.3	31
161	Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive–compulsive disorder. Biological Psychiatry, 1999, 45, 164-174.	0.7	65
162	Modulation of the firing activity of rat serotonin and noradrenaline neurons by (\hat{A}_{\pm}) pindolol. Biological Psychiatry, 1999, 45, 1163-1169.	0.7	31

#	Article	IF	CITATIONS
163	Venlafaxine in Treatment-Resistant Major Depression: A Canadian Multicenter, Open-Label Trial. Journal of Clinical Psychopharmacology, 1999, 19, 401-406.	0.7	68
164	Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive–compulsive disorder responses. Biological Psychiatry, 1998, 44, 313-323.	0.7	176
165	Effect of acute, short- and long-term milnacipran administration on rat locus coeruleus noradrenergic and dorsal raphe serotonergic neurons. Neuropharmacology, 1998, 37, 905-918.	2.0	67
166	Blockade of 5-Hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine. British Journal of Pharmacology, 1998, 125, 526-532.	2.7	56
167	Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission1These results have been reported in part in two publications (Haddjeri et al. 1996,) Tj ETQq1 I	1 0. 78431	4 4g BT /Ove
168	Effect of Ergotamine on Serotonin-Mediated Responses in the Rodent and Human Brain. Neuropsychopharmacology, 1998, 19, 365-380.	2.8	16
169	In vivo electrophysiological assessment of the agonistic properties of flibanserin at pre- and postsynaptic 5-HT1A receptors in the rat brain. , 1998, 29, 392-405.		15
170	Effect of long-term administration of duloxetine on the function of serotonin and noradrenaline terminals in the rat brain. Naunyn-Schmiedeberg's Archives of Pharmacology, 1998, 357, 600-610.	1.4	25
171	Effect of the reversible monoamine oxidase-A inhibitor befloxatone on the rat 5-hydroxytryptamine neurotransmission. European Journal of Pharmacology, 1998, 343, 179-192.	1.7	30
172	Augmentation strategies in treatment resistant depression: Preclinical and clinical aspects. European Psychiatry, 1998, 13, 207S-207S.	0.1	1
173	Long-Term Antidepressant Treatments Result in a Tonic Activation of Forebrain 5-HT1AReceptors. Journal of Neuroscience, 1998, 18, 10150-10156.	1.7	307
174	Early onset of therapeutic action in depression and greater efficacy of antidepressant treatments. International Clinical Psychopharmacology, 1997, 12, S21-S28.	0.9	19
175	Modulation of the firing activity of noradrenergic neurones in the rat locus coeruleus by the 5-hydroxtryptamine system. British Journal of Pharmacology, 1997, 120, 865-875.	2.7	130
176	Selective Activation of Postsynaptic 5-HT1A Receptors Induces Rapid Antidepressant Response. Neuropsychopharmacology, 1997, 16, 333-338.	2.8	155
177	The Effect of Tryptophan Depletion on Mood in Medication-Free, Former Patients with Major Affective Disorder. Neuropsychopharmacology, 1997, 16, 294-297.	2.8	54
178	Effect of acute and repeated versus sustained administration of the 5-HT1A receptor agonist ipsapirone: electrophysiological studies in the rat hippocampus and dorsal raphe. Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 356, 303-311.	1.4	55
179	Functional characterization of 5â€HT _{1D} autoreceptors on the modulation of 5â€HT release in guineaâ€pig mesencephalic raphe, hippocampus and frontal cortex. British Journal of Pharmacology, 1996, 118, 681-689.	2.7	27
180	Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends in Neurosciences, 1996, 19, 378-383.	4.2	626

#	Article	IF	Citations
181	Effects of long-term treatment with the $\hat{l}\pm 2$ -adrenoceptor antagonist mirtazapine on 5-HT neurotransmission. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 355, 20-29.	1.4	61
182	Autoregulatory properties of dorsal raphe 5-HT neurons: Possible role of electrotonic coupling and 5-HT1D receptors in the rat brain., 1996, 22, 54-62.		42
183	Pre- and post-synaptic effects of the 5-HT3 agonist 2-Methyl-5-HT on the 5-HT system in the rat brain. Synapse, 1995, 20, 54-67.	0.6	34
184	Alteration of Serotonin Release in the Guinea Pig Orbito-Frontal Cortex by Selective Serotonin Reuptake Inhibitors Relevance to Treatment of Obsessive-Compulsive Disorder. Neuropsychopharmacology, 1995, 13, 117-127.	2.8	112
185	5-HT1D Receptors Regulate 5-HT Release in the Rat Raphe Nuclei In Vivo Voltammetry and In Vitro Superfusion Studies. Neuropsychopharmacology, 1995, 13, 249-260.	2.8	67
186	Effect of acute and prolonged tianeptine administration on the 5-HT transporter: electrophysiological, biochemical and radioligand binding studies in the rat brain. Naunyn-Schmiedeberg's Archives of Pharmacology, 1995, 351, 111-118.	1.4	26
187	Effect of prolonged administration of tianeptine on 5-HT neurotransmission: an electrophysiological study in the rat hippocampus and dorsal raphe. Naunyn-Schmiedeberg's Archives of Pharmacology, 1995, 351, 119-125.	1.4	25
188	The Effects of Mirtazapine on the Interactions between Central Noradrenergic and Serotonergic Systems. CNS Drugs, 1995, 4, 13-17.	2.7	25
189	Blier and de Montigny reply. Trends in Pharmacological Sciences, 1995, 16, 17.	4.0	0
190	Effectiveness of Pindolol With Selected Antidepressant Drugs in the Treatment of Major Depression. Journal of Clinical Psychopharmacology, 1995, 15, 217-222.	0.7	282
191	Electrophysiologic Evidence for Desensitization of $\hat{l}\pm 2$ -Adrenoceptors on Serotonin Terminals Following Long-Term Treatment with Drugs Increasing Norepinephrine Synaptic Concentration. Neuropsychopharmacology, 1994, 10, 41-51.	2.8	82
192	Effect of long-term administration of antidepressant drugs on the 5-HT3 receptors that enhance the electrically evoked release of [3H]noradrenaline in the rat hippocampus. European Journal of Pharmacology, 1994, 271, 121-129.	1.7	23
193	Activation of 5-HT3 receptors enhances the electrically evoked release of [3H]noradrenaline in rat brain limbic structures. European Journal of Pharmacology, 1994, 256, 269-279.	1.7	49
194	Current advances and trends in the treatment of depression. Trends in Pharmacological Sciences, 1994, 15, 220-226.	4.0	1,040
195	Modulation of 5â€HT release in the guineaâ€pig brain following longâ€term administration of antidepressant drugs. British Journal of Pharmacology, 1994, 113, 485-495.	2.7	105
196	5-HT3 receptors which modulate [3H]5-HT release in the guinea pig hypothalamus are not autoreceptors. Synapse, 1993, 15, 143-148.	0.6	23
197	In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of $\hat{1}\pm 2$ -adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn-Schmiedeberg's Archives of Pharmacology, 1993, 347, 266-272.	1.4	97
198	Functional characterization of a 5â€HT ₃ receptor which modulates the release of 5â€HT in the guineaâ€pig brain. British Journal of Pharmacology, 1993, 108, 13-22.	2.7	60

#	Article	IF	Citations
199	Effect of repeated electroconvulsive shocks on serotonergic neurons. European Journal of Pharmacology, 1992, 211, 365-373.	1.7	35
200	Terminal serotonin autoreceptor function in the rat hippocampus is not modified by pertussis and cholera toxins. Naunyn-Schmiedeberg's Archives of Pharmacology, 1991, 344, 160-166.	1.4	19
201	Flerobuterol, \hat{a}^2 -adrenoceptor agonist, enhances serotonergic neurotransmission: an electrophysiological study in the rat brain. Psychopharmacology, 1991, 103, 357-365.	1.5	10
202	Differential responsiveness of the rat dorsal and median raphe 5-HT systems to 5-HT1 receptor agonists and p-chloroamphetamine. Synapse, 1990, 5, 120-133.	0.6	121
203	The benzodiazepine receptor inverse agonist DMCM decreases serotonergic transmission in rat hippocampus: An in viovo electrophysiological study. Synapse, 1990, 6, 175-178.	0.6	6
204	Differential Effect of Gepirone on Presynaptic and Postsynaptic Serotonin Receptors. Journal of Clinical Psychopharmacology, 1990, 10, 13S-20S.	0.7	62
205	Electrophysiological Investigation of the Effects of Antidepressant Treatments on Serotonin Receptors. , 1990, , 499-504.		6
206	Diurnal Variation in the Function of Serotonin Terminals in the Rat Hypothalamus. Journal of Neurochemistry, 1989, 52, 453-459.	2.1	24
207	Electrophysiological assessment of putative antagonists of 5-hydroxytryptamine receptors: a single-cell study in the rat dorsal raphe nucleus. Canadian Journal of Physiology and Pharmacology, 1989, 67, 98-105.	0.7	47
208	Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: an electrophysiological study in the rat brain. Naunyn-Schmiedeberg's Archives of Pharmacology, 1988, 337, 246-254.	1.4	153
209	Modifications of the Serotonin System by Antidepressant Treatments. Journal of Clinical Psychopharmacology, 1987, 7, 36S.	0.7	328
210	Short-term lithium treatment enhances responsiveness of postsynaptic 5-HT1A receptors without altering 5-HT autoreceptor sensitivity: An electrophysiological study in the rat brain. Synapse, 1987, 1, 225-232.	0.6	74
211	Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: Electrophysiological studies in the rat brain. Synapse, 1987, 1, 470-480.	0.6	420
212	Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: Electrophysiological studies in the rat brain. Naunyn-Schmiedeberg's Archives of Pharmacology, 1986, 333, 342-348.	1.4	290
213	Effect of repeated amiflamine administration on serotonergic and noradrenergic neurotransmission: Electrophysiological studies in the rat CNS. Naunyn-Schmiedeberg's Archives of Pharmacology, 1986, 334, 253-260.	1.4	28
214	Short-term lithium administration enhances serotonergic neurotransmission: Electrophysiological evidence in the rat CNS. European Journal of Pharmacology, 1985, 113, 69-77.	1.7	99
215	Effects of the two antidepressant drugs mianserin and indalpine on the serotonergic system: Single-cell studies in the rat. Psychopharmacology, 1984, 84, 242-249.	1.5	97
216	Effect of chronic tricyclic antidepressant treatment on the serotoninergic autoreceptor. Naunyn-Schmiedeberg's Archives of Pharmacology, 1980, 314, 123-128.	1.4	66